An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento in Subjects with Von Willebrand Disease
Phase of Trial: Phase IV
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Von Willebrand factor (Primary)
- Indications Von Willebrand disease
- Focus Therapeutic Use
- Sponsors CSL Behring
- 19 Aug 2017 Planned End Date changed from 1 Feb 2018 to 15 Feb 2018.
- 16 Aug 2017 Planned primary completion date changed from 1 Feb 2018 to 15 Feb 2018.
- 10 Jun 2017 Biomarkers information updated